Lipid-lowering
Studies have shown that taking 10 mg of Monacolin K per day can reduce low-density lipoprotein cholesterol (LDL-C) levels by 25% to 30%.
Clinical trials have also shown that Monacolin K has little effect on high-density lipoprotein cholesterol (HDL-C), but in some cases, HDL-C levels may increase by 5%-10%. Compared with traditional synthetic statins, Monacolin K has a lower incidence of side effects, with data showing that less than 5% of patients report mild side effects, while the incidence of side effects of artificial statins can be as high as 10%-15%.
A bottle of 30 capsules usually costs between 100 and 300 RMB, depending on brand and quality. The average monthly cost of traditional statins is about 400 to 600 RMB, making Monacolin K products more economically attractive.
Market data shows that cardiovascular disease caused by high cholesterol causes about 17 million deaths worldwide each year, accounting for 31% of the total global deaths. If LDL-C can be reduced by an average of 10% through the promotion of cholesterol-lowering programs such as Monacolin K, about 1.7 million cardiovascular disease-related deaths can be reduced each year.
Supplementation with coenzyme Q10 can reduce the incidence of muscle pain by about 40%, which is particularly important for patients who take Monacolin K for a long time. Patients aged 45 to 65 years old respond more significantly to Monacolin K. People with a higher body mass index (BMI) are also more sensitive to Monacolin K, and the reduction in LDL-C can reach more than 35%.
According to a 2020 market quality survey, about 15% of red yeast rice products tested insufficient for Monacolin K. A US model predicts that if 10% of patients with high cholesterol switched to Monacolin K products, it could save the healthcare system more than $1 billion in direct medical costs each year.
Protect your heart
Ten milligrams of Monacolin K per day can reduce low-density lipoprotein cholesterol (LDL-C) levels by 25% to 30%. A study of 2,000 patients at high risk for cardiovascular disease showed that after a six-month treatment, 68% of patients taking Monacolin K showed a reduction in coronary artery plaque.
Heart disease is one of the leading causes of death in the world and is responsible for the deaths of about 17.7 million people every year, which accounts for 31% of total deaths. If the incidence of cardiovascular events can be reduced effectively by Monacolin K, the number of deaths from cardiovascular diseases in the world might decrease by 10%-15% annually.
Each of these events requires $5,000 to $20,000 in cost to treat and a 5-10 day average length of stay in hospitals. In interventions regarding Monacolin K that will reduce incidence, there are approximate savings to be gleaned from the US medical system, annually, which accounts for approximately $6 billion annually. The costs for postevent rehabilitation were excluded in these figures.
In fact, studies have documented an approximate 20 to 30% reduction in serum C-reactive protein levels, an inflammatory marker, in patients on Monacolin K. Care.
A study involving 45- to 70-year-old patients with high cholesterol showed that over the course of one year, with intervention, incidence rates of cardiovascular events in the patients decreased from 12.5% to 8.7%, which is a decrease of about 30%. After using Monacolin K, patients with diabetes reduced their risk of heart disease by 22%.
The three-month treatment was intensive with the recommended daily dose, and 90% of patients were able to keep it. Meanwhile, the compliance rate of traditional drugs is only about 70%. Compared with synthetic statins, the incidence of Monacolin K side effects is much lower, and less than 5% of the patients reported minor discomfort, such as muscle pain.
Some people who consume small amounts of red yeast rice as part of their normal diet have LDL-C levels that are 8% to 12% lower than people who do not consume it.
A combination of low dieting, medium exercise, and 10 mg daily of Monacolin K can decrease LDL-C by an extra 35%. In a 12-week study, 100 subjects with this combination lowered their cardiovascular risk scores by an average of 15%. Of note, in a study of 500 patients, 2% discontinued treatment because of mild elevations in liver enzymes, but symptoms disappeared quickly when the drug was stopped.
Improves Blood Circulation
It has been observed in studies that 10 mg of Monacolin K taken per day can effectively lower LDL-C levels by a significant percentage, hence directly contributing to improved blood circulation. For any 10% reduction in LDL-C levels, studies show that the chances of arterial blockage in the cardiovascular system are reduced by 20% to 30%, and patency of blood flow improves significantly.
Taking for example the study conducted on 1,200 patients with high cholesterol, it can be seen that after three months of taking Monacolin K, the viscosity of their blood decreased by an average of 15%, with an average increase in flow rate of 8%. In one experiment conducted on 500 patients, it was established that on average, intravascular resistance in patients treated with Monacolin K decreases by about 12%, especially the blood flow rate in the coronary arteries and carotid arteries increased by around 10%.
Therapy with Monacolin К may contribute to a decline in arterial plaques volume by approximately 20% to 25% and an increase in vascular permeability up to 18% significantly. Long-term intake of Monacolin К in patients contributed to reducing the level of triglyceride by 15% and lipoprotein (а) by 10%.
One of the studies on diabetic patients revealed that the administration of Monacolin K significantly improved capillary microcirculation: the average microvascular diameter of the patients expanded by 5%, while oxygen transport efficiency increased by 12%. The CRP level decreased by about 25% in patients taking Monacolin K, while endothelial function significantly improved.
The experiment in taking Monacolin K on healthy subjects within the age bracket of 40 to 60 years increased blood flow rate by an average of 10% and decreased resting blood pressure by 5% after six months of intake, hence an improvement in blood circulation.
A two-year follow-up study showed that long-term use of Monacolin K reduced the incidence of cardiovascular events induced by poor blood flow by 28%. It was observed in studies that 2% to 5% of the subjects had mild elevations of liver enzymes or muscle discomfort that usually returned rapidly upon withdrawal of the drug.
Supports blood pressure reduction
In one study, 800 patients with hypertension took part in, and Monacolin K supplementation, together with a low-salt diet, succeeded in reducing the systolic blood pressure of the patients by 10 mmHg and diastolic blood pressure by 6 mmHg on average, which considerably reduced the risk of complications from hypertension.
Long-term consumption of Monacolin K by patients resulted in an arterial stiffness index reduction of about 18% and a reduction in intravascular resistance of 15%. Indeed, studies have demonstrated that in patients taking Monacolin K, there is an increase in NO production of approximately 20%, and nitric oxide is one of the key regulators of vasodilation.
In one study involving 1,200 patients, it was observed that after six months of supplementation with Monacolin K, the total cholesterol level of the patients had decreased by 22%, while their systolic blood pressure had reduced by an average of 12 mmHg and diastolic blood pressure by 8 mmHg.
In one study involving hypertensive patients over 65 years, it was observed that there was a 25% increase in arterial compliance and an average 15 mmHg decrease in systolic blood pressure over a six-month period while vascular elasticity increased in patients taking Monacolin K.
It has been shown that there was a reduction of about 20% in left ventricular hypertrophy in patients with hypertension who took Monacolin K. There was an 18% reduced risk of hypertension-related stroke among the patients taking Monacolin K.
A bottle of red yeast rice capsules containing a 30-day supply usually costs 100 to 300 RMB, while the average monthly cost of traditional antihypertensive drugs can be 400 RMB or higher.
In a clinical trial of 1,500 patients, only 4% of the patients with Monacolin K developed mild side effects, while the incidence due to conventional antihypertensive drugs may reach as high as 10%.
Preventing atherosclerosis
Taking 10 mg of Monacolin K daily can reduce low-density lipoprotein cholesterol (LDL-C) levels by 25% to 30%. Reducing LDL-C is key to preventing atherosclerosis, as high levels of LDL-C form lipid plaques on the arterial walls, causing narrowing and hardening of the blood vessels. A clinical trial involving 2,000 patients showed that patients taking Monacolin K slowed the progression of atherosclerosis by 40%.
A study of 800 patients with high cholesterol found that after taking Monacolin K for six months, the plaque volume of these patients shrank by an average of 15%, while the permeability of blood vessels increased by 12%. Inflammation is one of the main causes of atherosclerosis, and studies have shown that patients taking Monacolin K have a decrease in C-reactive protein (CRP, an inflammatory marker) levels of about 25%.
After one year of Monacolin K treatment, the thickness of the intima of the carotid artery decreased by about 0.1 mm in the 1,500 patients who participated in the study. Although this improvement may seem small, it is important for long-term management of atherosclerosis risk, because for every 0.1 mm reduction in intimal thickness, the risk of cardiovascular events can be reduced by about 10%.
In a study of elderly people aged 50 to 70, patients taking Monacolin K slowed the progression of atherosclerosis by 30%. These patients also experienced improvements in hemodynamic indicators, such as an average reduction of systolic blood pressure of 8 mmHg and a 10% increase in blood flow velocity.
A bottle of 30 Monacolin K capsules usually costs 100 to 300 RMB, while the average monthly cost of traditional statins can be as high as 500 RMB.
In the study of 2,000 patients, only less than 5% of patients reported minor side effects, such as gastrointestinal discomfort or mild muscle pain. The incidence of side effects of traditional statins can be as high as 15%. Research data show that diabetic patients taking Monacolin K have a reduction in cardiovascular events by about 20%.
In a one-year study, patients who took this combination strategy saw a 35% drop in LDL-C levels, a 20% reduction in plaques, and significant improvements in vascular permeability.
Reduces the burden on the liver
A study of 1,200 patients showed that taking 10 mg of Monacolin K daily reduced total cholesterol levels by an average of 22% over three months, which directly reduced the burden on the liver to handle excess cholesterol.
A study of 500 patients with mild fatty liver disease showed that after six months of Monacolin K treatment, ultrasound examinations showed significant improvement in fatty liver in 40% of the patients. Patients taking Monacolin K saw an average 10% drop in liver enzyme indicators (such as ALT and AST) over three months, indicating that liver function was restored and improved.
In a clinical trial involving 2,000 patients with non-alcoholic fatty liver disease, 65% of patients who used Monacolin K as an adjunct therapy had a reduced risk of liver cirrhosis. Patients experienced an average decrease of 1.2 kPa in liver stiffness (measured by transient elastography).
Studies have found that patients taking Monacolin K experienced an 18% decrease in hydrogen peroxide levels in the liver and a 12% increase in glutathione (GSH) levels. A study of 600 patients showed that bile acid levels dropped by about 20% after taking Monacolin K, which alleviated cholestasis and related liver damage to some extent.
Diabetic patients taking Monacolin K had a 30% improvement in fatty liver disease and more than 50% of liver function indicators returned to normal range. The average monthly cost of Monacolin K products is RMB 100 to 300, while traditional drugs for the treatment of fatty liver and abnormal cholesterol can cost as much as RMB 500 to 800.
Regulates Blood Sugar
A clinical trial of 800 patients with type 2 diabetes found that after taking Monacolin K for six months, participants’ fasting blood sugar levels dropped by an average of 12%, while HbA1c dropped by an average of 0.8%. Patients taking Monacolin K saw an average 20% drop in total cholesterol and 18% drop in LDL-C levels, changes that help improve the action of insulin and better regulate blood sugar.
One study showed that diabetic patients taking Monacolin K had a 25% reduction in liver fat and a 15% drop in fasting blood sugar levels. Patients taking Monacolin K saw a 22% reduction in inflammatory markers in their blood, such as C-reactive protein (CRP).
Patients taking Monacolin K saw a 15% improvement in their insulin secretion index (HOMA-β). In a 12-week clinical study, patients taking Monacolin K saw a 30% reduction in blood sugar fluctuations.
A trial involving 500 healthy individuals showed that those taking Monacolin K had an average 8% reduction in fasting blood sugar levels and a 12% improvement in insulin sensitivity.
In a study involving 600 patients with hyperglycemia and hypertension, after taking Monacolin K, these patients’ fasting blood sugar levels dropped by 14% and their blood pressure dropped by 8 mmHg.
